Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer

Silexion Therapeutics Corp

SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).
Increased MHC-I may enhance T cell recognition, supporting potential combination with anti-PD-1 therapies like Keytruda.
CEO Ilan Hadar said SIL204 may influence immune evasion pathways in addition to direct anti-tumor activity.
Pancreatic cancer is immunologically resistant; MHC-I loss is a key immune evasion mechanism in KRAS-driven tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.